Although pembrolizumab demonstrated an ORR of 22% among patients with PD-L1-positive advanced GC according to the Keynote-012 clinical trial, the subsequent trial regarding pembrolizumab among patients with advanced GC failed to show a significant advantage [33]. This evidence concerns the gene CD274 and gastric cancer.